Home » Reports » Broker Ratings » GlaxoSmithKline plc 6.2% Potential Upside Indicated by JP Morgan Cazenove
broker ratings

GlaxoSmithKline plc 6.2% Potential Upside Indicated by JP Morgan Cazenove

GlaxoSmithKline plc with EPIC/TICKER LON:GSK had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘NEUTRAL’ this morning by analysts at JP Morgan Cazenove. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. JP Morgan Cazenove have set their target price at 1670 GBX on its stock. This now indicates the analyst believes there is a possible upside of 6.2% from the opening price of 1572 GBX. Over the last 30 and 90 trading days the company share price has decreased 108.5 points and increased 22 points respectively.

 
GlaxoSmithKline plc LON:GSK has a 50 day moving average of 1,660.74 GBX and a 200 Day Moving Average share price is recorded at 1,626.97 GBX. The 1 year high stock price is 1745.56 GBX while the year low share price is currently 1363 GBX. There are currently 4,917,299,716 shares in issue with the average daily volume traded being 8,133,487. Market capitalisation for LON:GSK is £77,398,297,530 GBP.

 

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products.

You might also find these articles of interest:

Register here to be notified of future articles like this
Get all our broker ratings on Twitter as they are published!